EVEROLIMUS and PYREXIA

Overview

PYREXIA is the #9 most commonly reported adverse reaction for EVEROLIMUS, manufactured by Novartis Pharmaceuticals Corporation. There are 2,111 FDA adverse event reports linking EVEROLIMUS to PYREXIA. This represents approximately 2.0% of all 106,093 adverse event reports for this drug.

Patients taking EVEROLIMUS who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PYREXIA is a less commonly reported adverse event for EVEROLIMUS, but still significant enough to appear in the safety profile.

Other Side Effects of EVEROLIMUS

In addition to pyrexia, the following adverse reactions have been reported for EVEROLIMUS:

• DEATH — 6,301 reports
• MALIGNANT NEOPLASM PROGRESSION — 4,591 reports
• DIARRHOEA — 3,999 reports
• FATIGUE — 3,747 reports
• STOMATITIS — 3,154 reports
• NAUSEA — 2,783 reports
• DYSPNOEA — 2,613 reports
• DRUG INEFFECTIVE — 2,292 reports
• VOMITING — 2,091 reports
• DECREASED APPETITE — 2,085 reports

Other Drugs Associated with PYREXIA

The following drugs have also been linked to pyrexia in FDA adverse event reports:

Does EVEROLIMUS cause PYREXIA?

PYREXIA has been reported as an adverse event in 2,111 FDA reports for EVEROLIMUS. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PYREXIA with EVEROLIMUS?

PYREXIA accounts for approximately 2.0% of all adverse event reports for EVEROLIMUS, making it a notable side effect.

What should I do if I experience PYREXIA while taking EVEROLIMUS?

If you experience pyrexia while taking EVEROLIMUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages